Why the study?
Does i.v. disopyramide phosphate alter electrophysiologic parameters in cardiac transplant recipients with functional cardiac denervation?
Population
8 cardiac transplant recipients with documented functional cardiac denervation
Comparison
Disopyramide phosphate 2 mg/kg i.v. over 5 minutes vs Baseline (pre-drug administration)
Design
Case_series
Authors
Loading...
May warrant caution with disopyramide in transplant recipients; leaves open its risk-benefit profile in denervated hearts.
Does i.v. disopyramide phosphate alter electrophysiologic parameters in cardiac transplant recipients with functional cardiac denervation?
Disopyramide has markedly depressant direct electrophysiologic effects in the denervated heart, which are normally counteracted by its anticholinergic actions in the innervated heart.
Bexton et al. (1983) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: